PPAR : a dagger in the heart of the metabolic syndrome
Open accessThe DOI matches its Crossref record; 97 of the 100 references it cites were found in a registry or an index.
Abstract
Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both overexpression and activation of PPARδ result in increased mitochondrial biogenesis in the absence of an increase in PGC-1α mRNA in skeletal muscle in vivo (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The finding that overexpression of PPARδ in skeletal muscle of transgenic mice does not result in an increase in PGC-1α mRNA led to the conclusion that the increase in mitochondria is mediated directly by PPARδ (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast to the finding in mouse and rat skeletal muscle that PPARδ overexpression or activation does not result in an increase in PGC-1α mRNA, a number of studies have shown that PPARδ induces an increase in PGC-1α gene transcription, with a rapid increase in PGC-1α mRNA, in myotubes (19, 50, 51).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The regulation of PGC-1α expression by PPARδ differs markedly between skeletal muscle in vivo and myotubes in culture.”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Research works printed but not linked: 1
- [77]Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.
Cited by
Items 301–400 of 738
Quang, T. H., Ngân, N. T. T., Minh, C. V., Kiệm, P. V., Tài, B. H., Nhiệm, N. X., Thảo, N. P., Luyen, B. T. T., Yang, S. Y., & Kim, Y. H. (2012) · Phytotherapy Research · doi:10.1002/ptr.4871 · Cited by 35
“…expression of genes involved in the regulation of glucose, lipid, and cholesterol metabolism, cell growth, and cell differentiation by binding to specific PPREs at the enhancer sites of target genes (Balint and Nagy, 2006; Barish et al., 2006; Berger and Moller, 2002; Haluzik and Haluzik, 2006).”
BackgroundBartolomucci, A., Bresciani, E., Bulgarelli, I., Rigamonti, A. E., Pascucci, T., Levi, A., Possenti, R., Torsello, A., Locatelli, V., Müller, E. E., et al. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0110-0 · Cited by 35
Mikami, D., Kimura, H., Kamiyama, K., Torii, K., Kasuno, K., Takahashi, N., Yoshida, H., & Iwano, M. (2013) · Hypertension Research · doi:10.1038/hr.2013.157 · Cited by 35
Wolf, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.2009.00261.x · Cited by 35
Manio, M. C. C., Inoue, K., Fujitani, M., Matsumura, S., & Fushiki, T. (2016) · Physiological Reports · doi:10.14814/phy2.12625 · Cited by 35
Multitargeted bioactive ligands for PPAR s discovered in the last decade
Zhang, J., Liu, X., Xian-bin, X., Cheng, X., & Wang, R. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12806 · Cited by 35
Malek, M. A., Hoang, M.-H., Jia, Y., Lee, J. H., Jun, H. J., Lee, D., Lee, H. J., Lee, C., Lee, M. K., Hwang, B. Y., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.020 · Cited by 34
Ganß, R. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.02.003 · Cited by 34
Potential treatments for insulin resistance in the horse: A comparative multi-species review
Tinworth, K. D., Harris, P. A., Sillence, M. N., & Noble, G. K. (2009) · The Veterinary Journal · doi:10.1016/j.tvjl.2009.08.032 · Cited by 34
“The adipose- and muscle-localised peroxisome proliferatoractivated receptors PPARa, PPARc and PPARd are targets for dyslipidaemia and IR, because of their role in modulating lipid metabolism (Barish et al., 2006).”
BackgroundHiga, R., González, E., Pustovrh, M. C., White, V., Capobianco, E., Martínez, N., & Jawerbaum, A. (2006) · Molecular Human Reproduction · doi:10.1093/molehr/gal104 · Cited by 34
“…subtypes of PPARs, which are nuclear receptors that act as regulatory transcription factors, heterodimerize with retinoid X receptors and modulate gene expression of target genes containing peroxisome proliferator-responsive elements (PPREs) in response to ligand activation (Barish et al., 2006).”
BackgroundIitaka, D., Moodley, S., Shimizu, H., Bai, X.-H., & Liu, M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.015 · Cited by 33
Quang, T. H., Ngân, N. T. T., Minh, C. V., Kiệm, P. V., Thảo, N. P., Tài, B. H., Nhiệm, N. X., Song, S. B., & Kim, Y. H. (2011) · Carbohydrate Research · doi:10.1016/j.carres.2011.08.029 · Cited by 33
Ngân, N. T. T., Quang, T. H., Tài, B. H., Song, S. B., Lee, D., & Kim, Y. H. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf204768d · Cited by 33
Bortolotto, J. W., Margis, R., Ferreira, Â. C. B., Padoin, A. V., Mottin, C. C., & Guaragna, R. M. V. D. C. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9172-5 · Cited by 33
Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats
Wang, H., Liu, H., Jia, Z., Guan, G., & Yang, T. (2010) · PPAR Research · doi:10.1155/2010/601562 · Cited by 33
“Indeed, all three PPAR subtypes share common lipid-lowering properties [25–28], and PPARα [29–32] and PPARγ [33–36] exert similar renoprotective effects in animals or humans with diabetic nephropathy.”
BackgroundLi, W., Zhou, W. P., Song, S. B., Shim, S. H., & Kim, Y. H. (2014) · Journal of Natural Products · doi:10.1021/np500234f · Cited by 33
Thornton, S. M., Krolopp, J. E., & Abbott, M. J. (2016) · PPAR Research · doi:10.1155/2016/5465804 · Cited by 30
Barrera, G., Toaldo, C., Pizzimenti, S., Cerbone, A., Pettazzoni, P., Dianzani, M. U., & Ferretti, C. (2008) · PPAR Research · doi:10.1155/2008/524671 · Cited by 33
“At least three subtypes of PPARs have been identified: PPARα, the first isolated from mice liver in 1990 by Issemann and Green [4] and involved in fatty acid oxidation; PPARγ, identified by Tontonoz and collaborators as a transcription factor associated with adipocyte determination and differentiation [6]; and PPARβ/δ…”
MethodThe Metabolic Syndrome: An Overview and Proposed Mechanisms
Thomaz, F. S., John, O. D., Sinha, P., Shafie, S. R., & Worrall, S. (2024) · Obesities · doi:10.3390/obesities4030020 · Cited by 34
Chu, H., Jiang, L., Gao, B., Gautam, N., Alamoudi, J. A., Lang, S., Wang, Y., Duan, Y., Alnouti, Y., Cable, E. E., et al. (2020) · Translational research · doi:10.1016/j.trsl.2020.06.006 · Cited by 32
Chen, Z., Yu, B., Chen, L., Cheng, K., Lin, H.-J., & Cheng, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01212.x · Cited by 32
“It has recently been found that the maintenance PPARd levels in cardiomyocytes is crucial for their inotropic function (Cheng et al., 2004a,b; Barish et al., 2006).”
BackgroundNuclear receptors and AMPK: can exercise mimetics cure diabetes?
Wall, C. E., Yu, R. T., Atkins, A. R., Downes, M., & Evans, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0073 · Cited by 32
“Mechanistically, PPARs operate as ligand-inducible transcription factors constitutively bound to consensus response elements on chromatin in a heterodimer with the retinoid X receptors (RXRs) (Barish et al. 2006).”
BackgroundTranscriptional regulatory circuits controlling muscle fiber type switching
Liu, J., Liang, X., & Gan, Z. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4833-4 · Cited by 32
Linking αMSH with PPARγ in B16‐F10 melanoma
Maresca, V., Flori, E., Camera, E., Bellei, B., Aspite, N., Ludovici, M., Catricalà, C., Cardinali, G., & Picardo, M. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.01042.x · Cited by 32
“Three PPARs iso-forms have been identified in cell types from different lineages and are designated as a, b ⁄ d and c (Barish et al., 2006; Issemann and Green, 1990; Tontonoz et al., 1993).”
BackgroundPPAR Agonists and Cardiovascular Disease in Diabetes
Calkin, A. C., & Thomas, M. C. (2008) · PPAR Research · doi:10.1155/2008/245410 · Cited by 32
Schindler, C. (2007) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944707082662 · Cited by 32
“Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis [Barish et al. 2006].”
BackgroundControl of Peroxisome Proliferator-Activated Receptor Fate by the UbiquitinProteasome System
Genini, D., & Catapano, C. V. (2006) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890600928202 · Cited by 32
“Activated PPARδ has been shown to play a role in a variety of processes including cholesterol efflux, embryonic development, preadipocyte proliferation, wound healing, and lipid uptake in macrophages (6,24,25).”
BackgroundMyostatin deficiency is associated with lipidomic abnormalities in skeletal muscles
Baati, N., Feillet‐Coudray, C., Fouret, G., Vernus, B., Goustard, B., Coudray, C., Lecomte, J., Blanquet, V., Magnol, L., Bonnieu, A., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.06.017 · Cited by 31
PPARβ/δ activation of CD300a controls intestinal immunity
Tanaka, T., Tahara‐Hanaoka, S., Nabekura, T., Ikeda, K., Jiang, S. S., Tsutsumi, S., Inagaki, T., Magoori, K., Higurashi, T., Takahashi, H., et al. (2014) · Scientific Reports · doi:10.1038/srep05412 · Cited by 31
Gao, D., Zhang, Y.-L., Xu, P., Lin, Y., Yang, F. Q., Liu, J., Zhu, H.-W., & Xia, Z. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.12.034 · Cited by 31
Løvås, K., Røst, T. H., Skorve, J., Ulvik, R. J., Gudbrandsen, O. A., Bohov, P., Wensaas, A. J., Rustan, A. C., Berge, R. K., & Husebye, E. S. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00958.x · Cited by 31
Genini, D., Carbone, G. M., & Catapano, C. V. (2008) · PPAR Research · doi:10.1155/2008/195065 · Cited by 31
“This paradoxical response is similar to the effects of PPARδ on inflammatory gene expression in macrophages, where both receptor activation and knockout suppressed expression of a subset of target genes [31, 36].”
BackgroundResultInfluentialVedani, A., Descloux, A.-V., Spreafico, M., & Ernst, B. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2007.06.011 · Cited by 31
Yang, L., Olsson, B., Pfeifer, D., Jönsson, J., Zhou, Z. G., Jiang, X., Fredriksson, B. ‐., Zhang, H., & Sun, X. F. (2009) · Oncogene · doi:10.1038/onc.2009.370 · Cited by 30
“Studies have shown a wide range of PPAR-b agonists, including eicosanoids, fatty acids and some synthetic compounds (for example, GW501516); GW501516 is currently in a phase II clinical trial for dyslipidemia (Barish et al., 2006; Peraza et al., 2006; Takahashi et al., 2006).”
Hytönen, J. P., Leppänen, O., Bräsen, J. H., Schunck, W., Mueller, D., Jung, F., Mrowietz, C., Jastroch, M., von Bergwelt‐Baildon, M., Kappert, K., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306962 · Cited by 30
Dietary Apple Polyphenols Enhance Gastrocnemius Function in Wistar Rats
Nakazato, K., Song, H., & Waga, T. (2007) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31803df4bc · Cited by 30
PPARβ/δ ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation
Barroso, E., Rodríguez‐Rodríguez, R., Chacón, M. R., Maymó‐Masip, E., Ferrer‐Font, L., Salvadó, L., Salmerón, E., Wabistch, M., Palomer, X., Vendrell, J. J., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.02.010 · Cited by 29
Adu‐Amankwaah, J., Adekunle, A. O., Tang, Z., Bushi, A., Tan, R., Fu, L., Gong, Z., Ma, Z., Mprah, R., Noah, M. L. N., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155934 · Cited by 29
Liang, Y.-J., Liu, Y.-C., Chen, C., Lai, L., Shyu, K., Juang, S.-J., Wang, B.-W., & Leu, J.-G. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.03.100 · Cited by 29
Pattanakuhar, S., Pongchaidecha, A., Chattipakorn, N., & Chattipakorn, S. C. (2016) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2016.09.012 · Cited by 29
Kadayat, T. M., Shrestha, A., Jeon, Y. H., An, H., Kim, J., Cho, S. J., & Chin, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01882 · Cited by 29
The PPAR‐Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects
Spinelli, S., O'Brien, J. J., Bancos, S., Lehmann, G. M., Springer, D. L., Blumberg, N., Francis, C. W., Taubman, M. B., & Phipps, R. P. (2007) · PPAR Research · doi:10.1155/2008/328172 · Cited by 29
“protects against atherosclerosis by driving the reverse transport of cholesterol from peripheral cells to the liver for excretion [77, 113].”
BackgroundInfluentialChen, Z., Chen, L., & Cheng, J. (2013) · PPAR Research · doi:10.1155/2013/456042 · Cited by 29
Clinical Approaches for Mitochondrial Diseases
Hong, S., Kim, S., Kim, K., & Lee, H. (2023) · Cells · doi:10.3390/cells12202494 · Cited by 28
“It has a preference for increasing fatty acid oxidation and enhancing mitochondrial biogenesis [161–164 , 194 Elamipretide (SBT-272) has a distinct activity in restoring defective mitochondria compared to other chemical compounds described previously.”
BackgroundYuan, H., Kopelovich, L., Yin, Y., Lu, J., & Glazer, R. I. (2012) · Oncotarget · doi:10.18632/oncotarget.457 · Cited by 28
Muscle wasting and adipose tissue browning in infantile nephropathic cystinosis
Cheung, W. W., Cherqui, S., Ding, W. Q., Esparza, M. C., Zhou, P. H., Shao, J., Lieber, R. L., & MAK, R. H. K. (2015) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12056 · Cited by 28
PPARαIs Required for PPARδAction in Regulation of Body Weight and Hepatic Steatosis in Mice
Garbacz, W. G., Huang, J. T.-J., Higgins, L. G., Wahli, W., & Palmer, C. N. A. (2015) · PPAR Research · doi:10.1155/2015/927057 · Cited by 27
Mechanisms of Simple Hepatic Steatosis
Matherly, S. C., & Puri, P. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.005 · Cited by 27
Dongiovanni, P., & Valenti, L. V. C. (2013) · PPAR Research · doi:10.1155/2013/452061 · Cited by 27
Weiss, K., Mihály, J., Liebisch, G., Marosvölgyi, T., Schmitz, G., Décsi, T., & Rühl, R. (2011) · Lipids · doi:10.1007/s11745-011-3593-6 · Cited by 27
PPARδ agonists suppress angiogenesis in a VEGFR2-dependent manner
Meißner, M., Hrgović, I., Doll, M., & Kaufmann, R. (2010) · Archives of Dermatological Research · doi:10.1007/s00403-010-1091-y · Cited by 26
“The highest expression levels of PPARd are found in small intestine, colon, heart, adipose tissue, and brain [ 1 , 4, 10, 13].”
BackgroundAmmazzalorso, A., Lellis, L. D., Florio, R., Bruno, I., Filippis, B. D., Fantacuzzi, M., Giampietro, L., Maccallini, C., Perconti, S., Verginelli, F., et al. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13026 · Cited by 26
PPARδ-mediated mitochondrial rewiring of osteoblasts determines bone mass
Müller, D. I. H., Stoll, C., Palumbo‐Zerr, K., Böhm, C., Krishnacoumar, B., Ipseiz, N., Taubmann, J., Zimmermann, M., Böttcher, M., Mougiakakos, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65305-5 · Cited by 26
Lundell, K., Thulin, P., Hamsten, A., & Ehrenborg, E. (2007) · BMC Molecular Biology · doi:10.1186/1471-2199-8-70 · Cited by 26
Li, H., Fukuda, S., Hasegawa, Y., Kobayashi, H., Purevsuren, J., Mushimoto, Y., & Yamaguchi, S. (2009) · Brain and Development · doi:10.1016/j.braindev.2009.06.001 · Cited by 26
Hexarelin Signaling to PPARγ in Metabolic Diseases
Demers, A., Rodrigue‐Way, A., & Tremblay, A. (2008) · PPAR Research · doi:10.1155/2008/364784 · Cited by 26
“Over the recent years, with the unveiling of their ability to behave as master regulators of an array of genes that coordinate numerous pathways in lipid, glucose, and energy metabolism, the peroxisome proliferator-activated receptors (PPAR) have been considered important targets in the therapeutic…”
BackgroundMerit of Ginseng in the Treatment of Heart Failure in Type 1-Like Diabetic Rats
Tsai, C.-C., Chan, P., Chen, L., Chang, C. K., Liu, Z., & Lin, J. (2014) · BioMed Research International · doi:10.1155/2014/484161 · Cited by 25
NO to Obesity: Does Nitric Oxide Regulate Fat Oxidation and Insulin Sensitivity?
Joost, H., & Tschöp, M. H. (2007) · Endocrinology · doi:10.1210/en.2007-0866 · Cited by 25
“factor has recently been shown to be of central importance for fat oxidation in muscle (9).”
BackgroundCresser, J., Bonen, A., Chabowski, A., Stefanyk, L. E., Gulli, R. A., Ritchie, I. R. W., & Dyck, D. J. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00431.2009 · Cited by 25
The Role of PPARδ Signaling in the Cardiovascular System
Ding, Y., Yang, K. D., & Yang, Q. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00014-4 · Cited by 25
Joseph, F. N. (2014) · Frontiers in bioscience · doi:10.2741/4257 · Cited by 24
Bell, E. L., Shine, R. W., Dwyer, P., Olson, L., Truong, J. K., Fredenburg, R. A., Goddeeris, M. M., Stickens, D., & Tozzo, E. (2018) · Mitochondrion · doi:10.1016/j.mito.2018.02.006 · Cited by 24
Fan, L., Sweet, D. R., Fan, E., Prosdocimo, D. A., Madera, A., Jiang, Z., Padmanabhan, R., Haldar, S. M., Vinayachandran, V., & Jain, M. K. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101926 · Cited by 24
“While there are currently no PPARδ agonists in clinical use, promising studies in animals have demonstrated that activating PPARδ has beneficial effects on obesity, hypercholesterolemia, insulin resistance, and exercise endurance (20, 21).”
BackgroundHyperlipidemia and cardiovascular disease
Le, N. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199704000-00015 · Cited by 24
Gurnell, M. (2007) · PPAR Research · doi:10.1155/2007/83593 · Cited by 24
“PPARγ is the third member of a subdivision within the superfamily that also includes PPARα and PPARδ [25, 26].”
BackgroundKondoh, K., Tsuji, N., Asanuma, K., Kobayashi, D., & Watanabe, N. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.06.028 · Cited by 24
Are “exercise pills” the answer to the growing problem of physical inactivity?
Warden, S. J., & Fuchs, R. K. (2008) · British Journal of Sports Medicine · doi:10.1136/bjsm.2008.053512 · Cited by 24
Gonçalez, J. L., Shen, J., & Li, W. (2024) · Cells · doi:10.3390/cells13242077 · Cited by 23
“PPAR γ is a nuclear receptor that regulates expression of genes associated with mitochondrial biogenesis and antioxidant responses [181].”
PPARD is an Inhibitor of Cartilage Growth in External Ears
Zhang, Z., Duan, Y., Wu, Z., Zhang, H., Ren, J., & Huang, L. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19714 · Cited by 23
Non-classical Transcriptional Activity of Retinoic Acid
Noy, N. (2016) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-024-0945-1_7 · Cited by 23
Ikeda, S., Kawahara‐Miki, R., Iwata, H., Sugimoto, M., & Shinichi, K. U. M. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-04003-1 · Cited by 23
Physical activity in prevention and treatment of diabetes
Apor, P. (2009) · Orvosi Hetilap · doi:10.1556/oh.2009.28550 · Cited by 22
The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
Thomas, M. C., Jandeleit-Dahm, K. A. M., & Tikellis, C. (2012) · PPAR Research · doi:10.1155/2012/456529 · Cited by 22
Quang, T. H., Hương, T. T., Minh, C. V., Kiệm, P. V., Hương, H. T., Ngân, N. T. T., Nhiệm, N. X., Tùng, N. H., Thảo, N. P., Thủy, Đ. T. T., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.089 · Cited by 22
Kim, M. C., Kwon, H. C., Kim, S., Kim, H. S., & Um, B. H. (2011) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.59.834 · Cited by 22
Quang, T. H., Ngân, N. T. T., Minh, C. V., Kiệm, P. V., Yến, P. H., Tài, B. H., Nhiệm, N. X., Thảo, N. P., Anh, H. L. T., Luyen, B. T. T., et al. (2012) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c12-00550 · Cited by 22
Rieck, M., Wedeken, L., Müller‐Brüsselbach, S., Meißner, W., & Müller, R. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06037.x · Cited by 22
Carbaprostacyclin, a PPARδ agonist, ameliorates excess lipid accumulation in diabetic rat placentas
Kurtz, M., Capobianco, E., Martínez, N., Fernández, J., Higa, R., White, V., & Jawerbaum, A. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.03.008 · Cited by 22
The Impact of Current and Novel anti-diabetic Therapies On Cardiovascular Risk
Ussher, J. R., Sutendra, G., & Jaswal, J. S. (2012) · Future Cardiology · doi:10.2217/fca.12.68 · Cited by 21
Li, W., Yan, X., Sun, Y. N., Ngan, T. T., Shim, S. H., & Kim, Y. H. (2014) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2014.047 · Cited by 21
“…of genes involved in the regulation of glucose, lipid, and cholesterol metabolism by binding to specifi c peroxisome proliferator response elements (PPREs) in the enhancer sites of target genes (Berger and Moller, 2002; Balint and Nagy, 2006; Barish et al., 2006; Haluzik and Haluzik, 2006).”
BackgroundShould We Use PPAR Agonists to Reduce Cardiovascular Risk?
Robinson, J. G. (2008) · PPAR Research · doi:10.1155/2008/891425 · Cited by 21
“The more recently discovered PPAR-δ has also been found to be a powerful regulator of fatty acid catabolism and energy homeostasis [6].”
BackgroundVelkov, T., Lim, M. L. R., Capuano, B., & Prankerd, R. J. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.04.011 · Cited by 21
Bhurruth-Alcor, Y., Røst, T. H., Jorgensen, M. R., Kontogiorgis, C. A., Skorve, J., Cooper, R. G., Sheridan, J. M., Hamilton, W. D. O., Heal, J. R., Berge, R. K., et al. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00146e · Cited by 21
Hematopoietic knockdown of PPARδ reduces atherosclerosis in LDLR−/− mice
Li, G., Chen, C., Laing, S. D., Ballard, C., Biju, K. C., Reddick, R. L., Clark, R. A., & Li, S. (2015) · Gene Therapy · doi:10.1038/gt.2015.78 · Cited by 21
Nuclear Hormone Receptor Modulators for the Treatment of Diabetes and Dyslipidemia
Meinke, P. T., Wood, H. B., & Szewczyk, J. W. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41006-x · Cited by 21
The Treatment of Dyslipidemia—What's Left in the Pipeline?
Rau, O., Zettl, H., Popescu, L. N., Steinhilber, D., & Schubert‐Zsilavecz, M. (2008) · ChemMedChem · doi:10.1002/cmdc.200700165 · Cited by 21
Peroxisome Proliferator-Activated Receptors in Lung Cancer
Keshamouni, V. G., Han, S., & Roman, J. (2007) · PPAR Research · doi:10.1155/2007/90289 · Cited by 20
Charrier, A., Wang, L., Stephenson, E. J., Ghanta, S. V., Ko, C.-W., Croniger, C. M., Bridges, D., & Buchner, D. A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00234.2016 · Cited by 20
Yamamoto, K., Tamura, T., Henmi, K., Kuboyama, T., Yanagisawa, A., Matsubara, M., Takahashi, Y., Suzuki, M., Saito, J., Ueno, K., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01200 · Cited by 20
Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics
Ferrari, A., Longo, R., Silva, R., Mitro, N., Caruso, D., De Fabiani, E., & Crestani, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.008 · Cited by 19
YY1 repressing peroxisome proliferator-activated receptor delta promoter
He, C.-Q., Ding, N., & Fan, W. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9632-1 · Cited by 19
Adamkiewicz, J., Kaddatz, K., Rieck, M., Wilke, B., Müller‐Brüsselbach, S., & Müller, R. (2007) · PROTEOMICS · doi:10.1002/pmic.200601003 · Cited by 19
Iqbal, A., Yu, H., Jiang, P., & Zhao, Z. (2022) · Genes · doi:10.3390/genes13101828 · Cited by 18
“activities as its counterpart, it is articulated in a wider range of tissues, including the heart, skeletal muscle, and liver [36,37].”
BackgroundMetformin Protects Auditory Hair Cells from Gentamicin-Induced Toxicity in vitro
Glutz, A., Leitmeyer, K., Setz, C., Brand, Y., & Bodmer, D. (2015) · Audiology and Neurotology · doi:10.1159/000438918 · Cited by 18
Karsenty, J., Landrier, J., Rousseau‐Ralliard, D., Masson, V. R., Margotat, A., Deprez, P., Lechêne, P., Grynberg, A., Lairon, D., Planells, R., et al. (2012) · European Journal of Nutrition · doi:10.1007/s00394-012-0488-0 · Cited by 18
DLBS3233 increases glucose uptake by mediating upregulation of PPARγ and PPARδ expression
Nailufar, F., Tandrasasmita, O. M., & Tjandrawinata, R. R. (2011) · Biomedicine & Preventive Nutrition · doi:10.1016/j.bionut.2010.12.002 · Cited by 18
Yamada, K., Kobayashi, H., Bo, R., Purevsuren, J., Mushimoto, Y., Takahashi, T., Hasegawa, Y., Taketani, T., Fukuda, S., & Yamaguchi, S. (2016) · Brain and Development · doi:10.1016/j.braindev.2016.08.004 · Cited by 18
Geese, W. J., Achanzar, W. E., Rubin, C. J., Hariharan, N., Cheng, P. T. W., Tomlinson, L., Ordway, N. D., Dracopoli, N. C., DelMonte, T. A., Hui, L., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830a6ea0 · Cited by 18
Quinoa and Chia Modulate AMPK/PPAR-ɣ Signaling in High-Fat Diet–Induced Obesity Rat Model
Omran, N. H., El-Bahy, A. A. Z., Hosny, H. T. A., & Handoussa, H. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00388-5 · Cited by 17
“2007), highly expressed in muscles (Barish et al. 2006).”
Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment
Misal, S., Patil, V. M., Ramaa, C. S., & Lavecchia, A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108693 · Cited by 17
Metadata
- Authors
- Barish, G. D.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Barish, G. D.
- ORCID
- Barish, G. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-01
- Volume
- 116
- Issue
- 3
- Pages
- 590-597
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1386117
- OpenAlex
- W1987601141
- Cited by
- 641
- References
- 100
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 29 · 2014: 31 · 2013: 39 · 2012: 46
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- March of Dimes Foundation
- Larry L. Hillblom Foundation
- National Institutes of Health (U19DK62434)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (P50HL56989, P50HL056989)
- National Institute of Diabetes and Digestive and Kidney Diseases (U19 DK-62434, U19DK062434, F32DK071478)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- PPARδ, PPARα, PPARγ, metabolic syndrome, insulin resistance, hypertriglyceridemia, obesity, fatty acid degradation, adipose tissue, skeletal muscle, macrophage inflammation, atherosclerosis, nuclear receptors, weight gain, physical endurance
- MeSH terms
- Animals, Humans, Myocardium, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.